Phage susceptibility testing methods or 'phagograms': where do we stand and where should we go?

被引:1
|
作者
Kolenda, Camille [1 ,2 ]
Jourdan, Julie [1 ]
Roussel-Gaillard, Tiphaine [1 ]
Medina, Mathieu [1 ,2 ]
Laurent, Frederic [1 ,2 ]
机构
[1] Hosp Civils Lyon, Inst Agents Infect, Serv bacteriol, Lyon, France
[2] Univ Claude Bernard Lyon 1, Univ Lyon, CIRI Ctr Int Rech Infectiol, Team StaPath,Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France
关键词
BACTERIOPHAGE THERAPY; EFFICACY;
D O I
10.1093/jac/dkae325
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Phage therapy is a highly promising approach to address the challenge that is presented by the global burden of antimicrobial resistance. Given the natural specificity of phages, phage susceptibility testing (PST) is a prerequisite for successful personalized therapy, allowing the selection of active phages from large and diverse collections. However, the issue of an easy-to-use and standardized technique remains. In this review, we describe the principles, advantages and drawbacks of two routinely used PST techniques: plaque and growth kinetic assays. These are labour-intensive and time-consuming methods that require automation of one or more steps, including preparation of test panels, incubation, reading and analysis of results. In addition to automation, there is an urgent need to establish a reference method to enable efficient of PST techniques selection of therapeutic phages. We discuss knowledge gaps and parameters that need to be investigated to work towards this goal.
引用
收藏
页码:2742 / 2749
页数:8
相关论文
共 50 条
  • [21] Vaccines for COVID-19: Where do we stand in 2021?
    Sharma, Ketaki
    Koirala, Archana
    Nicolopoulos, Katrina
    Chiu, Clayton
    Wood, Nicholas
    Britton, Philip N.
    PAEDIATRIC RESPIRATORY REVIEWS, 2021, 39 : 22 - 31
  • [22] Photodynamic Therapy for Field Cancerization in the Skin: Where Do We Stand?
    Bakirtzi, Katerina
    Papadimitriou, Ilias
    Vakirlis, Efstratios
    Lallas, Aimilios
    Sotiriou, Eleni
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2023, 13 (04):
  • [23] Catheter ablation of atrial fibrillation in the elderly: Where do we stand?
    Traub, Darren
    Daubert, James P.
    McNitt, Scott
    Zareba, Wojciech
    Hall, Burr
    CARDIOLOGY JOURNAL, 2009, 16 (02) : 113 - 120
  • [24] Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
    Mohammad Sadeghi, Hosna
    Adeli, Ida
    Mousavi, Taraneh
    Daniali, Marzieh
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    LIFE-BASEL, 2021, 11 (08):
  • [25] Immunosuppressive treatment for giant cell arteritis: where do we stand?
    Pipitone, N.
    Salvarani, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (02) : S5 - S6
  • [26] Medical treatment for benign prostatic hyperplasia: Where do we stand?
    Rossanese, Marta
    Crestani, Alessandro
    Inferrera, Antonino
    Giannarini, Gianluca
    Bartoletti, Riccardo
    Tubaro, Andrea
    Ficarra, Vincenzo
    UROLOGIA JOURNAL, 2019, 86 (03) : 115 - 121
  • [27] Microneedling: Where do we stand now? A systematic review of the literature
    Ramaut, Lisa
    Hoeksema, Henk
    Pirayesh, Ali
    Stillaert, Filip
    Monstrey, Stan
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2018, 71 (01): : 1 - 14
  • [28] Gene Therapy and Hemophilia: Where Do We Go from Here?
    Bolous, Nancy S.
    Bhatt, Nidhi
    Bhakta, Nickhill
    Neufeld, Ellis J.
    Davidoff, Andrew M.
    Reiss, Ulrike M.
    JOURNAL OF BLOOD MEDICINE, 2022, 13 : 559 - 580
  • [29] Chronic Myeloid Leukemia: Where Do We Go Now? Introduction
    Cortes, Jorge E.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S374 - S375
  • [30] Gene therapy clinical trials, where do we go? An overview
    Arabi, Fatemeh
    Mansouri, Vahid
    Ahmadbeigi, Naser
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153